Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Payables (2016 - 2026)

Neuroone Medical Technologies filings provide 15 years of Payables readings, the most recent being $934196.0 for Q1 2026.

  • On a quarterly basis, Payables rose 2.57% to $934196.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $934196.0, a 2.57% increase, with the full-year FY2025 number at $1.0 million, down 1.83% from a year prior.
  • Payables hit $934196.0 in Q1 2026 for Neuroone Medical Technologies, up from $552332.0 in the prior quarter.
  • In the past five years, Payables ranged from a high of $1.0 million in Q3 2024 to a low of $325027.0 in Q2 2022.
  • Median Payables over the past 5 years was $861638.0 (2022), compared with a mean of $785761.1.
  • Biggest five-year swings in Payables: soared 194.99% in 2023 and later plummeted 38.4% in 2025.
  • Neuroone Medical Technologies' Payables stood at $861638.0 in 2022, then fell by 11.8% to $760000.0 in 2023, then dropped by 2.04% to $744525.0 in 2024, then dropped by 25.81% to $552332.0 in 2025, then surged by 69.14% to $934196.0 in 2026.
  • The last three reported values for Payables were $934196.0 (Q1 2026), $552332.0 (Q4 2025), and $1.0 million (Q3 2025) per Business Quant data.